240 related articles for article (PubMed ID: 37513358)
41. Design and synthesis of the novel oleanolic acid-cinnamic acid ester derivatives and glycyrrhetinic acid-cinnamic acid ester derivatives with cytotoxic properties.
Wang R; Yang W; Fan Y; Dehaen W; Li Y; Li H; Wang W; Zheng Q; Huai Q
Bioorg Chem; 2019 Jul; 88():102951. PubMed ID: 31054427
[TBL] [Abstract][Full Text] [Related]
42. Molecular docking, QSAR, pharmacophore modeling, and dynamics studies of some chromone derivatives for the discovery of anti-breast cancer agents against hormone-dependent breast cancer.
Arvindekar SA; Mohole S; Patil A; Mane P; Arvindekar A; Mali SN; Thorat B; Rawat R; Sharma S
J Biomol Struct Dyn; 2023; 41(24):14757-14770. PubMed ID: 36995997
[TBL] [Abstract][Full Text] [Related]
43. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA
Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, Characterization, and Biological Study of 3-Trifluoromethylpyrazole Tethered Chalcone-Pyrrole and Pyrazoline-Pyrrole Derivatives.
Kisan Rasal N; Bhaskar Sonawane R; Vijay Jagtap S
Chem Biodivers; 2021 Oct; 18(10):e2100504. PubMed ID: 34409724
[TBL] [Abstract][Full Text] [Related]
45. Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF-7 breast cancer cells by targeting tubulin colchicine binding site.
Wang G; Liu W; Gong Z; Huang Y; Li Y; Peng Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):139-144. PubMed ID: 31724435
[TBL] [Abstract][Full Text] [Related]
46. 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.
Lamie PF; Philoppes JN
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):864-879. PubMed ID: 32208772
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors.
Rahimzadeh Oskuei S; Mirzaei S; Reza Jafari-Nik M; Hadizadeh F; Eisvand F; Mosaffa F; Ghodsi R
Bioorg Chem; 2021 Jul; 112():104904. PubMed ID: 33933802
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and anti-proliferative activity of a novel 1,2,3-triazole tethered chalcone acetamide derivatives.
Vanaparthi S; Bantu R; Jain N; Janardhan S; Nagarapu L
Bioorg Med Chem Lett; 2020 Aug; 30(16):127304. PubMed ID: 32631524
[TBL] [Abstract][Full Text] [Related]
49. Structure-activity relationships reveal a 2-furoyloxychalcone as a potent cytotoxic and apoptosis inducer for human U-937 and HL-60 leukaemia cells.
Del Rosario H; Saavedra E; Brouard I; González-Santana D; García C; Spínola-Lasso E; Tabraue C; Quintana J; Estévez F
Bioorg Chem; 2022 Oct; 127():105926. PubMed ID: 35717804
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, Anticancer Activity and Molecular Modeling Studies of Novel Chalcone Derivatives Containing Indole and Naphthalene Moieties as Tubulin Polymerization Inhibitors.
Wang G; Peng Z; Li Y
Chem Pharm Bull (Tokyo); 2019 Jul; 67(7):725-728. PubMed ID: 30982797
[TBL] [Abstract][Full Text] [Related]
51. New Hybrid Scaffolds Based on Carbazole-Chalcones as Potent Anticancer Agents.
Rashid F; Zaib S; Ibrar A; Ejaz SA; Saeed A; Iqbal J; Khan I
Anticancer Agents Med Chem; 2021; 21(9):1082-1091. PubMed ID: 32698741
[TBL] [Abstract][Full Text] [Related]
52. Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives.
Guan YF; Liu XJ; Yuan XY; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Li W; Zhang SY
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443487
[TBL] [Abstract][Full Text] [Related]
53. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds.
El-Meligie S; Taher AT; Kamal AM; Youssef A
Eur J Med Chem; 2017 Jan; 126():52-60. PubMed ID: 27744186
[TBL] [Abstract][Full Text] [Related]
55. Design, Synthesis, and Anti-Cervical Cancer and Reversal of Tumor Multidrug Resistance Activity of Novel Nitrogen-Containing Heterocyclic Chalcone Derivatives.
Yang Z; Liu ZY; Ablise M; Maimaiti A; Mutalipu Z; Alimujiang Y; Aihaiti A
Molecules; 2023 Jun; 28(11):. PubMed ID: 37299013
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents.
Reddy MV; Su CR; Chiou WF; Liu YN; Chen RY; Bastow KF; Lee KH; Wu TS
Bioorg Med Chem; 2008 Aug; 16(15):7358-70. PubMed ID: 18602831
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and Characterization of New Series of 1,3-5-Triazine Hydrazone Derivatives with Promising Antiproliferative Activity.
H Al Rasheed HHA; M Malebari AM; A Dahlous KA; El-Faham A
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545272
[TBL] [Abstract][Full Text] [Related]
58. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
59. Thiazole-Chalcone Hybrids as Prospective Antitubercular and Antiproliferative Agents: Design, Synthesis, Biological, Molecular Docking Studies and In Silico ADME Evaluation.
Kasetti AB; Singhvi I; Nagasuri R; Bhandare RR; Shaik AB
Molecules; 2021 May; 26(10):. PubMed ID: 34064806
[TBL] [Abstract][Full Text] [Related]
60. New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
Hagar FF; Abbas SH; Abdelhamid D; Gomaa HAM; Youssif BGM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200357. PubMed ID: 36351754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
